Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 736-742

  Azambuja, D ^a   Natkunam, Y ^b   Biasoli, I ^a   Lossos, I S ^c   Anderson, M W ^b   Morais, J C ^a   Spector, N ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

CD68; Hodgkin's lymphoma; Macrophages; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD163 ANTIGEN; CD68 ANTIGEN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CLASSICAL HODGKIN LYMPHOMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857534118     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr157     Document Type: Article

References (22)

1. Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies. Ann Oncol 2007; 18 (Suppl 9): ix71-ix79.
2. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339(21): 1506-1514.
3. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008; 49(9): 1668-1680.
4. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351(21): 2159-2169.
5. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11(4): 1467-1473.
6. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362(10): 875-885.
7. DeVita VT Jr, Costa J. Toward a personalized treatment of Hodgkin's disease. N Engl J Med 2010; 362(10): 942-943.
8. Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010; 7(6): 301-302.
9. Nguyen TT, Schwartz EJ, West RB et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005; 29(5): 617-624.
10. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004; 36(5): 347-354.
11. Stein H, Delsol G, Pileri SA et al. Classical Hodgkin lymphoma, Introduction In Swerdlow SH, Campo E, Harris NL (eds), et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC 2008; 326-329.
12. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31(11): 1860-1861.
13. Azambuja D, Lossos IS, Biasoli I et al. Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. Leuk Lymphoma 2009; 50(11): 1830-1836.
14. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10(7): 657-662.
15. de Jong D, Rosenwald A, Chhanabhai M et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25(7): 805-812.
16. Diepstra A, van Imhoff GW, Schaapveld M et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009; 27(23): 3815-3821.
17. Spector N, Milito CB, Biasoli I et al. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 2005; 46(9): 1301-1306.
18. Natkunam Y, Mason DY. Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice? Lab Invest 2006; 86(8): 742-747.
19. Zu Y, Steinberg SM, Campo E et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk Lymphoma 2005; 46(5): 693-701.
20. Pulford KA, Sipos A, Cordell JL et al. Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol 1990; 2(10): 973-980.
21. Kamper P, Bendix K, Hamilton-Dutoit S et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96(2): 269-276.
22. Baumforth KR, Birgersdotter A, Reynolds GM et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173(1): 195-204.